Literature DB >> 14532767

Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis.

Hyung L Kim1, Arie S Belldegrun, Danielo G Freitas, Matthew H T Bui, Ken-ryu Han, Frederick J Dorey, Robert A Figlin.   

Abstract

PURPOSE: Renal cell carcinoma (RCC) can present with a wide range of signs and symptoms. To our knowledge we report the first study to describe the frequency of paraneoplastic findings in a modern RCC series and assess the prognostic significance of each finding.
MATERIALS AND METHODS: Using the kidney cancer database at our institution 1,046 patients undergoing nephrectomy for RCC between 1989 and 2001 were assessed. The prognostic significance of symptoms present at diagnosis and findings on preoperative laboratory evaluation were examined in a univariate analysis as well as on multivariate analysis controlling for TNM stage, Fuhrman grade and Eastern Cooperative Oncology Group performance status (ECOG-PS).
RESULTS: Mean followup to date of death or last contact for all patients was 40.3 months. Median time to death was 19.3 months. Most paraneoplastic signs and symptoms correlated with poor survival, although on multivariate analysis hypoalbuminemia, weight loss, anorexia and malaise predicted shorter survival. The frequency of each of these findings was 19.9%, 22.9%, 10.6% and 19.1%, respectively. Cachexia, defined as the presence of at least 1 of these findings, was noted in 35.3% of patients. Cachexia did not predict a higher recurrence rate in patients with localized disease and only malaise correlated with a decreased likelihood of responding to immunotherapy.
CONCLUSIONS: Cachexia, defined as hypoalbuminemia, weight loss, anorexia or malaise, predicts worse survival after controlling for well established indicators of prognosis (TNM stage, Fuhrman grade and ECOG-PS). Consideration should be given to expanding the ECOG-PS to include measures for cachexia when applied to patients with RCC.

Entities:  

Mesh:

Year:  2003        PMID: 14532767     DOI: 10.1097/01.ju.0000092764.81308.6a

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  49 in total

1.  Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma.

Authors:  Wassim Kassouf; Robert Siemens; Christopher Morash; Louis Lacombe; Michael Jewett; Larry Goldenberg; Joseph Chin; Michael Chetner; Christopher G Wood; Simon Tanguay; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2009-02       Impact factor: 1.862

2.  Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma.

Authors:  I Yildiz; F Sen; L Kilic; M Ekenel; C Ordu; I Kilicaslan; E Darendeliler; H M Tunc; U Varol; S Bavbek; M Basaran
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

Review 3.  Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.

Authors:  Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki
Journal:  World J Urol       Date:  2018-06-01       Impact factor: 4.226

4.  Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy.

Authors:  Daniel M Moreira; Boris Gershman; Christine M Lohse; Stephen A Boorjian; John C Cheville; Bradley C Leibovich; Robert Houston Thompson
Journal:  World J Urol       Date:  2016-02-25       Impact factor: 4.226

5.  Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.

Authors:  Wassim Kassouf; Leonardo L Monteiro; Darrel E Drachenberg; Adrian S Fairey; Antonio Finelli; Anil Kapoor; Jean-Baptiste Lattouf; Michael J Leveridge; Nicholas E Power; Frederic Pouliot; Ricardo A Rendon; Robert Sabbagh; Alan I So; Simon Tanguay; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2018-05-31       Impact factor: 1.862

Review 6.  Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients.

Authors:  Tracy M Downs; Matthew Schultzel; Helen Shi; Catherine Sanders; Zunera Tahir; Georgia Robins Sadler
Journal:  Crit Rev Oncol Hematol       Date:  2008-11-06       Impact factor: 6.312

7.  A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.

Authors:  J-F Rossi; S Négrier; N D James; I Kocak; R Hawkins; H Davis; U Prabhakar; X Qin; P Mulders; B Berns
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

8.  A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

Authors:  Deepa Rao; Zeeshan Butt; Sarah Rosenbloom; Don Robinson; Jamie Von Roenn; Timothy M Kuzel; David Cella
Journal:  J Pain Symptom Manage       Date:  2009-04-08       Impact factor: 3.612

9.  Dermatomyositis associated with gallbladder carcinoma: A case report.

Authors:  Qing-Feng Ni; Guo-Qing Liu; Li-Yong Pu; Liang-Liang Kong; Lian-Bao Kong
Journal:  World J Hepatol       Date:  2013-04-27

10.  Staging of renal cell carcinoma: Current concepts.

Authors:  John S Lam; Tobias Klatte; Alberto Breda
Journal:  Indian J Urol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.